Evidence map›Paper›PMID 41653213›Full record

ReviewCurrent oncology reports2026

Research Report on NUF2-Targeted Therapy for Digestive System Cancers: from Mechanism to Clinical Translation.

Luxi Yang, Zhonghong Xiong, Jing Yang, Jingsong Mei, Jinsen Wei, Yali Liu, Yumin Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luxi Yang *Gansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Zhonghong Xiong *The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Jing Yang *The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Jingsong MeiThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Jinsen WeiThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Yali LiuCuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, Gansu, China. wo_lyl@163.com.
Yumin LiGansu Provincial Key Laboratory of Environmental Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China. liym_1@yeah.net.

Funding

Cuiying Scientific Training Program for Undergraduates of The Second Hospital & Clinical Medical School, Lanzhou University CYXZ2024-06he Fundamental Research Funds for the Central Universities of Lanzhou University lzujbky-2022-sp08the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital CY2022-QN-A19, CY2022-QN-A11the Innovation and Entrepreneurship Project for Young Talents of Lanzhou Science and Technology Bureau 2023-4-18the International science and technology cooperation project of Gansu Provincial Science and Technology Department 2023YFWA0009the Major Science and Technology Project of Gansu Province 22ZD6FA050 and 22JR9KA002the Natural Science Foundation of Gansu 25JRRA625the Pioneering Discipline Partnership Project 537000-561119501the Project of Gansu Provincial Department of Education 2021jyjbgs-02the Project of Gansu Provincial Development and Reform Commission 2022-2024the Science and Technology Program Project of Gansu Provincial Natural Science Foundation 25JRRA590the Special Funding for Open and Shared Large-Scale Instruments and Equipment of Lanzhou University LZU-GXJJ-2025-003
6 · The paper itself

Abstract

purpose of reviewThis review synthesizes evidence on NUF2 in digestive system cancers, delineates its oncogenic mechanisms, and evaluates its potential as a diagnostic and therapeutic target, addressing unmet needs for these high-incidence, poor-prognosis malignancies. RECENT

findingsNUF2, a key cell cycle protein, is significantly overexpressed in digestive system cancers. Mechanistic studies reveal that it promotes tumorigenesis by driving genomic instability, inhibiting apoptosis, inducing epithelial–mesenchymal transition, and remodeling the tumor immune microenvironment. Emerging therapeutic strategies–including natural compounds (e.g., berberine, fisetin) and peptide-based vaccines–shows preclinical efficacy in targeting NUF2. NUF2 represents a promising biomarker and therapeutic target for digestive system cancers. While preclinical evidence is compelling, clinical translation remains at an early stage. Future efforts should focus on large-scale clinical validation, optimizing targeted interventions, and developing combinatorial approaches to improve patient outcomes.

Indexed as

Cell Cycle ProteinsDigestive System NeoplasmsMolecular Targeted TherapyAnimalsAntineoplastic AgentsApoptosisBiomarkers, TumorEpithelial-Mesenchymal TransitionHumansTumor MicroenvironmentAntineoplastic AgentsBiomarkers, TumorCell Cycle ProteinsApoptosisDigestive system cancersEpithelial-mesenchymal transitionGenomic instabilityNUF2Oxidative stressTumor microenvironment

Identifiers

PMID41653213

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.